• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

子宫内膜异位症的遗传背景:ESR2 和 CYP19A1 基因是否可能成为其发病的潜在危险因素?

The Genetic Background of Endometriosis: Can ESR2 and CYP19A1 Genes Be a Potential Risk Factor for Its Development?

机构信息

Laboratory of Cancer Genetics, Department of Pathology, Polish Mother's Memorial Hospital Research Institute, Rzgowska 281/289, 93-338 Lodz, Poland.

Department of Operative Gynaecology and Oncological Gynaecology, Polish Mother's Memorial Hospital Research Institute, Rzgowska 281/289, 93-338 Lodz, Poland.

出版信息

Int J Mol Sci. 2020 Nov 3;21(21):8235. doi: 10.3390/ijms21218235.

DOI:10.3390/ijms21218235
PMID:33153202
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7663510/
Abstract

Endometriosis is defined as the presence of endometrial foci, localized beyond their primary site, i.e., the uterine cavity. The etiology of this disease is rather complex. Its development is supported by hormonal, immunological, and environmental factors. During recent years, particular attention has been focused on the genetic mechanisms that may be of particular significance for the increased incidence rates of endometriosis. According to most recent studies, ESR2 and CYP19A1 genes may account for the potential risk factors of infertility associated with endometriosis. The paper presents a thorough review of the latest reports and data concerning the genetic background of the risk for endometriosis development.

摘要

子宫内膜异位症是指子宫内膜病灶出现在子宫腔以外的部位。其病因较为复杂,发病机制与激素、免疫和环境等因素有关。近年来,人们对遗传机制的关注日益增加,因为这些机制可能与子宫内膜异位症发病率的增加密切相关。根据最近的研究,ESR2 和 CYP19A1 基因可能是导致子宫内膜异位症相关不孕的潜在危险因素。本文对子宫内膜异位症发病风险的遗传背景的最新研究进展进行了综述。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f997/7663510/7976054c3bcf/ijms-21-08235-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f997/7663510/1d8ab6543828/ijms-21-08235-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f997/7663510/7976054c3bcf/ijms-21-08235-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f997/7663510/1d8ab6543828/ijms-21-08235-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f997/7663510/7976054c3bcf/ijms-21-08235-g002.jpg

相似文献

1
The Genetic Background of Endometriosis: Can ESR2 and CYP19A1 Genes Be a Potential Risk Factor for Its Development?子宫内膜异位症的遗传背景:ESR2 和 CYP19A1 基因是否可能成为其发病的潜在危险因素?
Int J Mol Sci. 2020 Nov 3;21(21):8235. doi: 10.3390/ijms21218235.
2
Association between single nucleotide polymorphism of the CYP19A1 and ESR2 genes and endometriosis.CYP19A1和ESR2基因单核苷酸多态性与子宫内膜异位症之间的关联。
Arch Gynecol Obstet. 2021 Aug;304(2):439-445. doi: 10.1007/s00404-021-06051-5. Epub 2021 Apr 7.
3
An Analysis of and Gene Expression Levels in Women With Endometriosis.子宫内膜异位症患者中 和 基因表达水平分析。
In Vivo. 2020 Jul-Aug;34(4):1765-1771. doi: 10.21873/invivo.11970.
4
Polymorphisms in the 3'UTR Region of ESR2 and CYP19A1 Genes in Women With Endometriosis.子宫内膜异位症女性中ESR2和CYP19A1基因3'UTR区域的多态性
Eur J Obstet Gynecol Reprod Biol. 2020 Jul;250:241-245. doi: 10.1016/j.ejogrb.2020.05.023. Epub 2020 May 21.
5
Functional Expression of FSH Receptor in Endometriotic Lesions.在子宫内膜异位症病灶中 FSH 受体的功能表达。
J Clin Endocrinol Metab. 2016 Jul;101(7):2905-14. doi: 10.1210/jc.2016-1014. Epub 2016 May 25.
6
Polymorphisms in ESR1, ESR2 and HSD17B1 genes are associated with fertility status in endometriosis.ESR1、ESR2 和 HSD17B1 基因的多态性与子宫内膜异位症的生育状态有关。
Gynecol Endocrinol. 2011 Jun;27(6):425-33. doi: 10.3109/09513590.2010.495434. Epub 2010 Jun 29.
7
Epigenetic alterations of CYP19A1 gene in Cumulus cells and its relevance to infertility in endometriosis.卵丘细胞中CYP19A1基因的表观遗传改变及其与子宫内膜异位症不孕的相关性。
J Assist Reprod Genet. 2016 Aug;33(8):1105-13. doi: 10.1007/s10815-016-0727-z. Epub 2016 May 11.
8
IGF-I stimulates ERβ and aromatase expression via IGF1R/PI3K/AKT-mediated transcriptional activation in endometriosis.在子宫内膜异位症中,胰岛素样生长因子-I(IGF-I)通过IGF1R/PI3K/AKT介导的转录激活作用刺激雌激素受体β(ERβ)和芳香化酶的表达。
J Mol Med (Berl). 2016 Aug;94(8):887-97. doi: 10.1007/s00109-016-1396-1. Epub 2016 Feb 22.
9
Endometriosis: Perspective, lights, and shadows of etiology.子宫内膜异位症:病因的视角、亮点和阴影。
Biomed Pharmacother. 2018 Oct;106:163-174. doi: 10.1016/j.biopha.2018.06.109. Epub 2018 Jun 27.
10
Gene expression profiles separate endometriosis lesion subtypes and indicate a sensitivity of endometrioma to estrogen suppressive treatments through elevated ESR2 expression.基因表达谱分离子宫内膜异位症病变亚型,并通过升高 ESR2 表达表明内异症囊肿对雌激素抑制治疗敏感。
BMC Med. 2023 Nov 23;21(1):460. doi: 10.1186/s12916-023-03166-1.

引用本文的文献

1
KLF5 silencing restrains proliferation, invasion, migration and angiogenesis of gallbladder carcinoma cells by transcriptional regulation of PDGFA.KLF5基因沉默通过对血小板衍生生长因子A(PDGFA)的转录调控来抑制胆囊癌细胞的增殖、侵袭、迁移和血管生成。
J Cancer Res Clin Oncol. 2024 Dec 20;151(1):11. doi: 10.1007/s00432-024-06059-9.
2
Diagnostic and therapeutic approaches for endometriosis: a patent landscape.子宫内膜异位症的诊断与治疗方法:专利态势
Arch Gynecol Obstet. 2024 Mar;309(3):831-842. doi: 10.1007/s00404-023-07151-0. Epub 2023 Aug 25.
3
Overview of Avian Sex Reversal.

本文引用的文献

1
Endometriosis and nuclear receptors.子宫内膜异位症与核受体。
Hum Reprod Update. 2019 Jul 1;25(4):473-485. doi: 10.1093/humupd/dmz005.
2
New biomarkers in endometriosis.子宫内膜异位症的新生物标志物。
Adv Clin Chem. 2019;89:59-77. doi: 10.1016/bs.acc.2018.12.002.
3
[Correlation between polymorphism of CYP19A1, GSTM1, GSTT1 and GSTP1 gene and endometriosis].[细胞色素P450 19A1、谷胱甘肽S-转移酶M1、谷胱甘肽S-转移酶T1和谷胱甘肽S-转移酶P1基因多态性与子宫内膜异位症的相关性]
鸟类性别反转概述。
Int J Mol Sci. 2023 May 5;24(9):8284. doi: 10.3390/ijms24098284.
4
Endometriosis-Associated Ovarian Cancer: What Are the Implications for Women with Intact Endometrioma Planning for a Future Pregnancy? A Reproductive Clinical Outlook.子宫内膜异位症相关卵巢癌:对有完整子宫内膜异位瘤且计划未来妊娠的女性有何影响?生殖临床展望。
Biomolecules. 2022 Nov 21;12(11):1721. doi: 10.3390/biom12111721.
5
Functional Implications of Estrogen and Progesterone Receptors Expression in Adenomyosis, Potential Targets for Endocrinological Therapy.雌激素和孕激素受体表达在子宫腺肌病中的功能意义,内分泌治疗的潜在靶点
J Clin Med. 2022 Jul 28;11(15):4407. doi: 10.3390/jcm11154407.
6
Polyphenols as a Diet Therapy Concept for Endometriosis-Current Opinion and Future Perspectives.多酚作为子宫内膜异位症的饮食治疗概念:现状与展望。
Nutrients. 2021 Apr 18;13(4):1347. doi: 10.3390/nu13041347.
Zhonghua Yi Xue Za Zhi. 2019 Feb 19;99(7):515-519. doi: 10.3760/cma.j.issn.0376-2491.2019.07.008.
4
Aberrant DNA methylation suppresses expression of estrogen receptor 1 (ESR1) in ovarian endometrioma.异常的 DNA 甲基化抑制卵巢子宫内膜异位症中雌激素受体 1(ESR1)的表达。
J Ovarian Res. 2019 Feb 6;12(1):14. doi: 10.1186/s13048-019-0489-1.
5
MicroRNAs in endometriosis: biological function and emerging biomarker candidates†.子宫内膜异位症中的 microRNAs:生物学功能和新兴的生物标志物候选物†。
Biol Reprod. 2019 May 1;100(5):1135-1146. doi: 10.1093/biolre/ioz014.
6
Plasma miRNAs Display Limited Potential as Diagnostic Tools for Endometriosis.血浆 miRNA 作为子宫内膜异位症诊断工具的潜力有限。
J Clin Endocrinol Metab. 2019 Jun 1;104(6):1999-2022. doi: 10.1210/jc.2018-01464.
7
Increased circulating miR-370-3p regulates steroidogenic factor 1 in endometriosis.循环 miR-370-3p 的增加调节子宫内膜异位症中的类固醇生成因子 1。
Am J Physiol Endocrinol Metab. 2019 Mar 1;316(3):E373-E382. doi: 10.1152/ajpendo.00244.2018. Epub 2018 Dec 21.
8
Differentially-Expressed miRNAs in Ectopic Stromal Cells Contribute to Endometriosis Development: The Plausible Role of miR-139-5p and miR-375.异位基质细胞中差异表达的 miRNAs 促进子宫内膜异位症的发展:miR-139-5p 和 miR-375 的可能作用。
Int J Mol Sci. 2018 Nov 28;19(12):3789. doi: 10.3390/ijms19123789.
9
Farnesoid X Receptor Agonist GW4064 Inhibits Aromatase and ERβ Expression in Human Endometriotic Stromal Cells.法尼醇 X 受体激动剂 GW4064 抑制人子宫内膜间质细胞中的芳香酶和 ERβ 表达。
Reprod Sci. 2019 Aug;26(8):1111-1120. doi: 10.1177/1933719118808912. Epub 2018 Nov 14.
10
Role of miR‑449b‑3p in endometriosis via effects on endometrial stromal cell proliferation and angiogenesis.miR-449b-3p 通过对子宫内膜间质细胞增殖和血管生成的影响在子宫内膜异位症中的作用。
Mol Med Rep. 2018 Sep;18(3):3359-3365. doi: 10.3892/mmr.2018.9341. Epub 2018 Jul 31.